Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.

Cancer research - 15 Jan 2004

Mizokami Atsushi, Koh Eitetsu, Fujita Hiroshi, Maeda Yuji, Egawa Masayuki, Koshida Kiyoshi, Honma Seijiro, Keller Evan T, Namiki Mikio

Abstract excerpt

Despite an initial response to androgen deprivation therapy, prostate cancer (PCa) progresses eventually from an androgen-dependent to an androgen-independent phenotype. One of the mechanisms of relapse is antiandrogen withdrawal phenomenon caused by mutation of 877th amino acid of androgen receptor (AR). In the present study, we established a method to measure the concentration of androstenediol (adiol) in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Androgens

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Division

Share to Dihydrotestosterone

Share to Genes, Reporter

Share to Prostatic Hyperplasia

Share to Prostatic Neoplasms

Share to Receptors, Androgen

Source

Identifiers

PMID: 14744796
DOI: 10.1158/0008-5472.can-03-0130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.PMID 14744796Read ↗

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.Semantic proximity Read ↗

Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.Semantic proximity Read ↗

Molecular basis for the antiandrogen withdrawal syndromeSemantic proximity Read ↗

Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.Semantic proximity Read ↗

Biochanin-A inhibits the activity of androgen receptor mutants to suppress the development of prostate cancerSemantic proximity Read ↗

Amplification and co-regulators of androgen receptor gene in prostate cancer.Semantic proximity Read ↗

Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.Semantic proximity Read ↗

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Semantic proximity Read ↗

Androgen receptor as a target in androgen-independent prostate cancer.Semantic proximity Read ↗

Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.Semantic proximity Read ↗

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.Semantic proximity Read ↗

Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.